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There have been suggestions from previous studies that patients with Charcot–Marie–Tooth disease (CMT) have weaker dominant
hand muscles. Since all studies to date have included a heterogeneous group of CMT patients we decided to analyse hand strength in 43
patients with CMT1X. We recorded handedness and the MRC scores for the ﬁrst dorsal interosseous and abductor pollicis brevis
muscles, median and ulnar nerve compound motor action potentials and conduction velocities in dominant and non-dominant hands.
Twenty-two CMT1X patients (51%) had a weaker dominant hand; none had a stronger dominant hand. Mean MRC scores were
signiﬁcantly higher for ﬁrst dorsal interosseous and abductor pollicis brevis in non-dominant hands compared to dominant hands.
Median nerve compound motor action potentials were signiﬁcantly reduced in dominant compared to non-dominant hands. We
conclude that the dominant hand is weaker than the non-dominant hand in patients with CMT1X.
 2012 Elsevier B.V. All rights reserved.
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The degree of hand weakness in neurological diseases
such as Charcot-Marie-Tooth disease (CMT) is of particu-
lar importance since it has a large impact on day to day
functioning and quality of life [1]. A study of 124 patients
suggested that patients with Charcot-Marie-Tooth disease
(CMT) might be susceptible to overwork weakness when
comparing the strength of dominant to non-dominant
hand muscles [2]. However, a further study using hand
dynamometry on 28 patients with CMT did not show
any signiﬁcant diﬀerence in muscle strength between
dominant and non-dominant hands [3].0960-8966/$ - see front matter  2012 Elsevier B.V. All rights reserved.
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m.reilly@ion.ucl.ac.uk (M.M. Reilly).Overwork weakness in neuromuscular disease remains a
contentious issue. Initially it was used to explain apparent
activity-dependent weakness that developed in patients with
post-polio syndrome [4]. It has also been described in
patients with facioscapulohumeral muscular dystrophy [5].
However, trials of exercise in patients with CMT, myotonic
dystrophy, Guillain–Barre´ syndrome, chronic inﬂammatory
polyradiculoneuropathy (CIDP) and even post-polio syn-
drome have not shown deterioration inmuscle strength [6–8].
Charcot–Marie–Tooth (CMT) disease is a genetically
heterogeneous inherited neuropathy. Over 300 mutations
have been described in the Gap Junction Beta 1 (GJB1) gene
that cause an X-linked form of the disease (CMT1X), the
second commonest form of CMT [9] (http://www.mol-
gen.ua.ac.be/CMTMutations). Mutations in GJB1 cause
neuropathy through a loss of normal gene function [10].
GJB1 codes for a protein called Connexin 32. It is expressed
by both Schwann cells and oligodendrocytes and is thought
to act as a gap junction protein, though how loss of normal
function leads to axon loss is yet to be elucidated [9].
Table 1
List of mutations in 43 patients studied with CMT1X.
Number Mutation
1 c.-373G>A (50UTR)
2 p.Trp3Stop
3 p.Arg15Gln
4 p.Arg22Gln
5 p.Leu25Phe
6 p.Ala39Val
7 p.Ala40Thr
8 p.Ser42CysfsX45
9 p.Cys60Phe
10 p.Tyr65X
11 p.Gln80Lys
12 p.Val91Met
13 p.Val91Leu
14 p.Val91Gly
15 p.His94Arg
16 p.Arg107Trp
17 p.Arg142Gln
18 p.Arg142Trp
19 p.Phe153Ser
20 p.Tyrl 57Cys
21 p.Phe158Ser
22 p.Gly159Asp
23 p.Tyrl 60Cys
24 p.Arg164Gly
25 p.Leu165Pro
26 p.Cys173Arg
27 p.Val192Phe
28 p.Arg215Trp
29 p.Gly21Asn and
p.Met162Thr (same allele)
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motor and sensory neuropathy with distal wasting. Some
patients also develop a central nervous system phenotype,
which can either present acutely or chronically [11]. Males
are typically more severely aﬀected than females [12]. Elec-
trophysiological studies demonstrate intermediate slowing
of conduction velocities with features of demyelination
and axonal loss and a variation in involvement within
and between nerves [13].
Since previous studies investigating hand strength in
CMT have included a genetically mixed group of CMT
patients, we decided to look at hand muscle strength in a
single group of CMT patients, CMT1X. The aim of this
study was to determine whether there was any diﬀerence
in the strength of the muscles in patients with CMT1X
between dominant and non-dominant hands. We also
aimed to determine whether there were diﬀerences in
strength between hand muscles innervated by diﬀerent
nerves as has been described previously with abductor pol-
licis brevis (APB) being weaker than ﬁrst dorsal interosse-
ous (FDIO) [9,14]. For both analyses we examined whether
nerve conduction studies correlated with our muscle
strength ﬁndings.
2. Methods
We retrospectively reviewed the notes of 53 patients
attending the National Hospital for Neurology and Neuro-
surgery with a genetically conﬁrmed diagnosis of CMT1X.
We recorded handedness, age, gender, mutation, most
recent CMT neuropathy score (CMTNS) [15], most recent
MRC score for FDIO and APB and most recent median
and ulnar nerve compound motor action potentials
(CMAPs) and conduction velocities. Median CMAP was
recorded from the APB and ulnar CMAP from the abduc-
tor digiti minimi (ADM). For numerical analysis, MRC
strength scores of 4 and 4+ were converted to values of
3.5 and 4.5, respectively.
The FDIO score for the dominant hand was tabulated
against the FDIO score for the non-dominant hand and
distributions were examined. In order to examine whether
there was a diﬀerence in FDIO strength between hands,
various MRC scores were tested as a cut oﬀ. For example,
an FDIO score cut-oﬀ of 4 meant, we categorised scores
into 64 versus >4. These categories were compared
between the dominant and non-dominant hands using a
McNemar’s test to see whether the same proportion of
scores were considered to be 64 for both hands. Similar
comparisons were made for APB MRC scores.
In order to make comparisons between the dominant and
non-dominant hands in nerve conduction outcomes and in
MRC strength scores, the distribution of the diﬀerence in
outcome values between hands was assessed. Non-paramet-
ric Wilcoxon sign-rank tests (i.e. matched-pairs tests) were
used to compare skewed diﬀerences and paired t-tests were
used for normally distributed diﬀerences. Multilevel models
were performed to account for the non-independence ofobservations in the dominant and non-dominant hands,
where clustering was assumed to have occurred within each
patient [16]. Thesemultilevelmodels explore the relationship
between each of the outcomes with hand-dominance after
adjustment for age and gender. A p value <0.01 was consid-
ered signiﬁcant.
All statistical analyses were performed using Stata
(StataCorp. 2009. Stata Statistical Software: Release 11.
College Station, TX: StataCorp LP).3. Results
Of the 53 patients, nine were excluded because MRC
score was not adequately documented and a further one
was discounted due to having an additional diagnosis of
CIDP. This left 43 patients, 22 males and 21 females, with
29 diﬀerent mutations in the GJB1 gene (Table 1). Males
were statistically younger, with a mean age of 37.2 years
compared to 45.4 years for females (p < 0.01). Males had
a mean CMTNS of 15.2 (n = 10, SD +/4) and females
a CMTNS of 12.6 (n = 13, SD +/4.4). Seventy-three per-
cent of patients were examined by a single author (MMR).
In CMT1X patients, FDIO strength was higher in the
non-dominant hand for 15/43 (34.9%) individuals and
APB strength was higher in the non-dominant hand for
14/43 (32.6%) individuals. There were 22/43 (51.2%)
Table 3A
Comparison of MRC strength scores for FDIO and APB muscles in the
dominant hand.
FDIO 95% CI APB 95% CI P value
Mean MRC score 3.78 3.56, 4.00 3.38 3.02, 3.75 0.001
Abductor pollicis brevis (APB) muscle is signiﬁcantly weaker than the ﬁrst
dorsal interosseous (FDIO) muscle in the dominant hand of patients with
CMT1X, measured by mean MRC strength score.
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bined MRC score of FDIO and APB. No patient was
found to have a stronger dominant hand for either FDIO
or APB MRC strength scores individually or for the
combined score.
When we categorised individuals into MRC strength
scores of >4 and 64, there was a signiﬁcant diﬀerence
in strength according to hand-dominance. We identiﬁed
nine (20.9%) individuals who had a non-dominant FDIO
score >4 and a dominant FDIO score 64 (p = 0.003)
and eight (18.6%) patients who had a non-dominant APB
score >4 and a dominant APB score 64 (p = 0.005).
Using other MRC grades as a cut oﬀ did not show statisti-
cal signiﬁcance in our sample population.
The mean strength scores for FDIO and APB were sig-
niﬁcantly higher in non-dominant compared to dominant
hands (p < 0.0001; Table 2). After adjustment for age and
gender there was a mean 0.22 (95% CI: 0.12, 0.32) higher
FDIO score for non-dominant hands compared to domi-
nant hands and in a separate model there was a 0.30
(95% CI: 0.14, 0.47) higher APB score for non-dominant
hands compared to dominant hands. In addition, males
had a 1.14 (95% CI: 1.77, 0.52) lower APB score than
females.
Median nerve CMAPs were smaller in dominant hands
compared to non-dominant hands, though this diﬀerence
did not achieve statistical signiﬁcance, most likely due to
the small sample size (n = 18; p = 0.02; Table 2). There
was no signiﬁcant diﬀerence in ulnar nerve CMAPs
between dominant and non-dominant hands (n = 14;
p = 0.89; Table 2). There was no diﬀerence between domi-
nant and non-dominant hands for median and ulnar nerve
conduction velocities (data not shown).
When comparing FDIO to APB strength in the domi-
nant hand of CMT1X patients, we found that APB was sig-
niﬁcantly weaker (p = 0.001; Table 3A). After adjustment
for age and gender, there was a mean 0.40 diﬀerence in
score for APB compared to FDIO (95% CI: 0.64, 0.15;
p = 0.001). Furthermore, the associated nerve conduction
studies demonstrated that median nerve CMAPs (APB)
were signiﬁcantly lower than the ulnar nerve CMAPs
(ADM) in CMT1X patients (p < 0.0001; Table 3B). Simi-
larly, conduction velocities were signiﬁcantly slower in
median nerves compared to ulnar nerves (p = 0.0005; Table
3B).Table 2
Comparison of hand muscles’ strength and ulnar and median nerve conductio
Dominant hand 95% CI
Mean score FDIO 3.78 3.56, 4.00
Mean score APB 3.38 3.02, 3.75
CMAP median (APB, mV) 2.03 0.96, 3.10
CMAP ulnar (ADM, mV) 4.70 3.15, 6.25
Patients with CMT1X have a higher mean MRC strength score for the ﬁrst d
muscle in non-dominant hands compared to dominant hands. Median nerve co
in non-dominant hands whereas ulnar nerve CMAPs (measured on abductor
conﬁdence interval are shown.4. Discussion
We reviewed the notes of 43 patients with CMT1X and
demonstrated that patients with CMT1X had a weaker
dominant hand. Median nerve CMAPs were reduced in
the dominant compared to the non-dominant hand. Fur-
thermore, we showed that the APB muscle was weaker
than FDIO, conﬁrming previous suggestions that there is
a greater impact on median nerve function compared to
the ulnar nerve [9,14].
There are several limitations to note with this study.
Firstly, we used the MRC scoring system to measure hand
strength. A recent study demonstrated that while there is a
signiﬁcant correlation between MRC scoring for hand
muscles and muscle strength measured by the Rotterdam
intrinsic hand myometer the scale is not linear and there
is considerable overlap between MRC grades 4 and 5
[17]. However, the cut oﬀ for signiﬁcance occurred around
MRC grade 4 in our data set suggesting that the
boundary between grades 4 and 5 was not crucial for dem-
onstrating diﬀerence in strength between dominant and
non-dominant hands. One would expect that overwork
would exert its eﬀects over time so that diﬀerences should
increase with age; however, our patient sample size was
not large enough to assess the eﬀect of patient age, or dis-
ease severity, measured by the CMTNS, on hand strength.
Additionally, a larger patient sample would be necessary to
analyse the eﬀect of gender on hand strength although our
data was suggestive that the diﬀerence between dominant
and non-dominant hands was present in males and females
for both FDIO and APB muscles (data not shown). We
demonstrated a reduction in median nerve CMAP in the
dominant hand; however, only 18 of 43 patients had both
right and left median nerves assessed, thus this result was
not statistically signiﬁcant. We did not show any diﬀerencen studies between dominant and non-dominant hands.
Non-dominant hand 95% CI P value
4.00 3.80, 4.00 <0.0001
3.69 3.35, 4.02 0.0001
3.03 2.13, 3.93 0.02
4.86 3.48, 6.24 0.89
orsal interosseous (FDIO) muscle and the abductor pollicis brevis (APB)
mpound motor action potentials (CMAP) (measured on APB) were larger
digiti minimi, ADM) were similar between hands. Mean values with 95%
Table 3B
Comparison of nerve conduction studies between median and ulnar nerves.
Ulnar nerve (ADM) 95% CI Median nerve (APB) 95% CI P value
Mean CMAP (mV) 5.53 4.75, 6.31 2.71 1.90,3.51 <0.0001
Mean CV (m/s) 42.89 38.86, 46.93 34.98 31.47,38.48 0.0005
Median nerve Compound motor action potentials (CMAP) and conduction velocities (CV) (both measured on APB) were statistically lower than ulnar
nerve CMAPs and conduction velocities (measured on abductor digiti minimi, ADM). Mean values with 95% conﬁdence interval are shown.
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but this may be due to the ulnar nerve being less aﬀected in
CMT1X [12]. Conduction velocity measurements showed
no diﬀerence between dominant and non-dominant hands.
This was unsurprising since CMAP values and not conduc-
tion velocities have been shown to correlate with muscle
weakness and disease progression [10,18]. In addition,
although we used FDIO MRC score for the strength scor-
ing, the ADM was used to determine ulnar CMAP.
Reassuringly, our study has conﬁrmed several previous
observations reported in CMT1X patients. Firstly we have
shown that APB is weaker in males than in females. Addi-
tionally, our male subgroup was signiﬁcantly younger and
had a higher mean CMTNS. These ﬁndings all ﬁt with
males being more severely aﬀected with an earlier disease
onset [10,12]. We also showed that median nerve CMAPs
and conduction velocities were reduced compared to the
ulnar nerve consistent with the clinical observation of
APB weakness being greater than the ulnar innervated
hand muscles, conﬁrming previous ﬁndings [9,12,14].
Although the results in this study suggest the dominant
hand is weaker in patients with CMT1X, these results
should be conﬁrmed by a prospective blinded study, ideally
using muscle myometry, MRC scoring and nerve conduc-
tion studies. However, this study does highlight the need
to investigate hand strength in an aetiologically homoge-
nous population since previous hand strength studies in
CMT have used a mixed population of patients with all
forms of CMT [2,3].
It has been suggested in previous studies that a diﬀerence
in hand strength between dominant and non-dominant
hands may suggest that overwork weakness causes
increased muscle weakness as the dominant hand will be
used more by the patient [2]. Whether this extrapolation is
valid remains to be seen but it is an important issue as exer-
cise training to improve strength in CMT is a growing area
of research. The few studies, at present, do not show any
harmful eﬀects of exercise on CMT and may show some
subtle improvements [6,19]. However, it is important to
note that strengthening exercises in these studies concen-
trate on proximal muscles whereas the distal muscles are
more aﬀected in CMT [20]. While our study does suggest
that the dominant hand is weaker in patients with CMT1X,
it would be premature to suggest this is due to overwork
weakness. Hand weakness in CMT1X has many unex-
plained facets requiring further studies including the current
ﬁnding of increased weakness in the dominant hand and
also the greater involvement of the median innervatedmuscles compared to the ulnar innervated muscles as shown
in this and previous studies [9,12,14].Acknowledgements
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